Brought to you by 
Hikma gets rights to commercialize Theravance's Vibativ in the MENA region
29 May 2015
Executive Summary
Theravance Inc. (focused on respiratory, infectious, neurological, and GI motility diseases) has licensed Hikma Pharmaceuticals PLC (branded and nonbranded generics) exclusive rights to register, market, and distribute its once-daily injectable antibiotic Vibativ (telavancin) in 16 countries throughout the Middle East and North Africa (MENA) region.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Hikma gets rights to commercialize Theravance's Vibativ in the MENA region
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice